Toggle light / dark theme

Get the latest international news and world events from around the world.

Log in for authorized contributors

E.W. Dijkstra Archive: On the cruelty of really teaching computing science (EWD 1036)

For Dijkstra, programming was closer to mathematics than to a craft. The goal wasn’t to “get a feel” for code. The goal was to reason about it rigorously, to understand why it works before discovering whether it works.


The second part of this talk pursues some of the scientific and educational consequences of the assumption that computers represent a radical novelty. In order to give this assumption clear contents, we have to be much more precise as to what we mean in this context by the adjective “radical”. We shall do so in the first part of this talk, in which we shall furthermore supply evidence in support of our assumption.

The usual way in which we plan today for tomorrow is in yesterday’s vocabulary. We do so, because we try to get away with the concepts we are familiar with and that have acquired their meanings in our past experience. Of course, the words and the concepts don’t quite fit because our future differs from our past, but then we stretch them a little bit. Linguists are quite familiar with the phenomenon that the meanings of words evolve over time, but also know that this is a slow and gradual process.

It is the most common way of trying to cope with novelty: by means of metaphors and analogies we try to link the new to the old, the novel to the familiar. Under sufficiently slow and gradual change, it works reasonably well; in the case of a sharp discontinuity, however, the method breaks down: though we may glorify it with the name “common sense”, our past experience is no longer relevant, the analogies become too shallow, and the metaphors become more misleading than illuminating. This is the situation that is characteristic for the “radical” novelty.

How AI & Quantum Computing Will Transform Zero Trust Cybersecurity

By Chuck Brooks, president of Brooks Consulting International and one of Executive Mosaic’s GovCon Experts

In Zero Trust cybersecurity protocols there is no implicit trust of identity or privilege – inside or outside the network perimeter, and every person, device, application and transaction must be continuously verified.

Zero Trust is a framework that is adaptive and it has to be in today’s digital ecosystem. Emerging technologies such as artificial intelligence and quantum computing are no longer merely enablers but core disruptors. They broaden attack surfaces, but also offer significant defenses, and call for a rethinking of Zero Trust systems.

The PROOF We’re In A Simulation Is Hiding In Plain Sight

ATT Business: Switch to AT&T Business at business.att.com.
Shopify: Sign up for your one-dollar-per-month trial period at https://shopify.com/impact.

Welcome back to Impact Theory with Tom Bilyeu. In today’s episode, Tom Bilyeu dives deep into one of the most provocative questions facing science and philosophy: Do we really have free will, or are we all just highly sophisticated NPCs—non-player characters—running a program inside a vast, resource-efficient simulation? Drawing on groundbreaking neuroscience experiments, the story of Phineas Gage, quantum mechanics, and the work of leading thinkers like Robert Sapolsky, Tom Bilyeu challenges everything we think we know about choice, consciousness, and the true nature of reality.

But this isn’t an episode about nihilism. Instead, Tom Bilyeu reveals why embracing the truth of a stochastically deterministic universe can actually make life feel more meaningful, freeing us from the weight of the past and inspiring us to make the most of every moment—programmed or not. Get ready to question your assumptions and see the world from a whole new perspective.

00:00 — Intro.
01:38 — Part 1: It’s Biology All The Way Down.
14:22 — Part 2: Quantum Mechanics Bury the Notion of Free Will.
19:53 — Part 3: The Last Hiding Places of Free Will.
27:51 — Part 4: Why Being An NPC Is The Best News You’ll Ever Get.

Sign up for my AI Masterclass: https://tombilyeu.com/ai-masterclass.
Check us out wherever you get your podcasts:
Spotify: https://open.spotify.com/show/1nARKz2
Apple: https://podcasts.apple.com/us/podcast
Do you need my help?
STARTING a business: join me here inside ZERO TO FOUNDER (https://tombilyeu.com/zero-to-founder)
Get the exact systems, mindset shifts, and principles that built a $1B brand delivered straight to your inbox every week. Subscribe for free (https://tombilyeu.com)
Check out our Video game — Project Kyzen: (https://projectkyzen.io/)
Catch Me Streaming on Twitch — (/ tombilyeu)
Link to IT discord: / discord.
Tom’s Favorite Things List: https://amzn.to/41Ftt7e.

FOLLOW TOM:

BREAKTHROUGH CHOLESTEROL CURE Lowers LDL For Life

New LDL Drug Could Cure Heart Disease. Eli Lilly published Phase 1 data in the New England Journal of Medicine showing that a single IV infusion of a gene editing therapy called VERVE-102 lowered LDL cholesterol permanently. Well… the effect held for at least 18 months. Longevity Twitter immediately called it the cure for heart disease. The science is real. The hype is getting ahead of what the paper actually says. This episode walks through the Phase 1 Heart-2 trial — the data, the base-editing mechanism (which is NOT CRISPR), the one safety event nobody’s talking about, and how Eli Lilly’s CEO is publicly thinking about pricing a one-and-done cure.

HUME BODY POD DISCOUNT UP TO 50% OFF:
Code: LSN20
https://humehealth.com/pages/hume-bod… Latte: https://longevitylatte.shop TIMESTAMPS 0:00 — Cold Open 1:41 — Sponsor: Hume Body Pod 2:53 — Intro: The Cholesterol Paradox 4:48 — How Statins Work 5:36 — PCSK9 Targeting 7:38 — How VERVE-102 Works 9:16 — The Results 12:16 — Other Drugs and Pricing 15:12 — Natural Alternatives 17:42 — Other One and Done Drugs 18:40 — Longevity Latte SOURCES & LINKS NEJM paper (Vafai, Täubel, Patel, Kathiresan et al.): https://www.nejm.org/doi/full/10.1056… Eli Lilly press release on Phase 1 Heart-2 data: https://www.prnewswire.com/news-relea… ClinicalTrials.gov Heart-2 trial entry (NCT06164730): https://clinicaltrials.gov/study/NCT0… Verve Therapeutics FDA Fast Track designation announcement: https://vervetx.gcs-web.com/news-rele… Cohen and Hobbs 2006 NEJM paper (the foundational PCSK9 loss-of-function discovery): https://www.nejm.org/doi/abs/10.1056/.… Dave Ricks (Eli Lilly CEO) on Cheeky Pint with Patrick and John Collison: • Dave Ricks, CEO of Eli Lilly, on GLP-1s an… FOURIER trial (evolocumab cardiovascular outcomes): https://www.nejm.org/doi/full/10.1056… ODYSSEY OUTCOMES trial (alirocumab cardiovascular outcomes): https://www.nejm.org/doi/full/10.1056… PCSK9 LoF and diabetes (Mendelian randomization, Lancet Diabetes & Endocrinology): https://www.thelancet.com/journals/la… PCSK9 inhibition and diabetes risk review: https://pmc.ncbi.nlm.nih.gov/articles… StatPearls overview of PCSK9 inhibitors: https://www.ncbi.nlm.nih.gov/books/NB… Sardinia cholesterol paradox study: https://pmc.ncbi.nlm.nih.gov/articles… Statin pleiotropic effects review (mevalonate pathway): https://www.ncbi.nlm.nih.gov/pmc/arti… Berberine as a nature-made PCSK9 inhibitor review: https://www.ncbi.nlm.nih.gov/pmc/arti… Berberine for dyslipidaemias meta-analysis: https://pubmed.ncbi.nlm.nih.gov/30466… Pomegranate juice, carotid IMT, and LDL oxidation (Aviram 3-year study): https://www.clinicalnutritionjournal… LATEST EXCLUSIVE INTERVIEW: [Ariel Garten / Muse headset interview YouTube URL] ABOUT LONGEVITY SCIENCE NEWS Longevity Science News covers the latest breakthroughs in anti-aging research, regenerative medicine, longevity biotech, and the science of extending human healthspan and lifespan. Hosted by Emmett Short. Disclaimer: This video is for educational and informational purposes only and does not constitute medical advice. Consult a qualified clinician before making health or treatment decisions. EXCLUSIVE INTERVIEWS & BONUS CONTENT Patreon: https://patreon.com/u29506604?utm_med… YT Membership: / @longevitysciencenews PRODUCTION CREDITS Executive Producer – Keith Comito Host, Producer, Writer – Emmett Short.

Longevity Latte:
https://longevitylatte.shop.

TIMESTAMPS
0:00 — Cold Open.
1:41 — Sponsor: Hume Body Pod.
2:53 — Intro: The Cholesterol Paradox.
4:48 — How Statins Work.
5:36 — PCSK9 Targeting.
7:38 — How VERVE-102 Works.
9:16 — The Results.
12:16 — Other Drugs and Pricing.
15:12 — Natural Alternatives.
17:42 — Other One and Done Drugs.
18:40 — Longevity Latte.

SOURCES \& LINKS
NEJM paper (Vafai, Täubel, Patel, Kathiresan et al.): https://www.nejm.org/doi/full/10.1056
Eli Lilly press release on Phase 1 Heart-2 data: https://www.prnewswire.com/news-relea
ClinicalTrials.gov Heart-2 trial entry (NCT06164730): https://clinicaltrials.gov/study/NCT0
Verve Therapeutics FDA Fast Track designation announcement: https://vervetx.gcs-web.com/news-rele
Cohen and Hobbs 2006 NEJM paper (the foundational PCSK9 loss-of-function discovery): https://www.nejm.org/doi/abs/10.1056/.
Dave Ricks (Eli Lilly CEO) on Cheeky Pint with Patrick and John Collison: • Dave Ricks, CEO of Eli Lilly, on GLP-1s an…

The endoplasmic reticulum protein Erg28 restrains Mto1-Mto2-γ-TuSC-mediated microtubule assembly

This study demonstrates the moonlighting role of the conserved ER transmembrane protein Erg28 in inhibiting microtubule assembly and provides insights into the involvement of membrane-bound organelles in microtubule cytoskeleton organization.

Jacque Fresco: Apply the Methods of Science to the Social System!

I have to confess something about this interview.

I really liked Jacque Fresco. Not as a thinker I was supposed to admire, but as a person: the humor, the humility, the scientific curiosity still burning at 97.

That made the disagreements harder, not easier.

Fresco spent almost a century arguing one idea. We apply the methods of #science to engineering, to medicine, to flight. Then we run our economies and our politics on opinion, tradition, and the preferences of the financial elite.

He thought we had it exactly inverted. Rigor for the machines, guesswork for the humans.

“Technology was never the hard part. The harder question is what kind of society we want it to serve.”

NVIDIA Just Slapped Apple Silicon — RTX Spark

Linus has all the details of the NVIDIA RTX Spark SoC. He also wonders about the power consumption math of these edge AI PCs.

Unfortunately Microsoft Windows is still in the mix, NVIDIA doesn’t have an AI OS — yet.

Who will produce the first native AI device?

Who will create the AI OS that everyone will use? Who will make the operating system of tomorrow? Who will be the OS leader?


To learn more, please visit the YouTube Help Center: https://www.youtube.com/help

OpenAI’s quiet co-founder steps out

OpenAI co-founder Wojciech Zaremba doesn’t do many interviews.

We recently spoke about why he moved over to help run the company’s nonprofit arm.

His reaction to Anthropic speaking alongside the Pope: “I have more bias towards doing. Let’s actually solve the problems, and let’s speak about the exact plan.”


Wojciech Zaremba recently bought a copy of “House on Fire,” a 2011 memoir by epidemiologist William Foege about the campaign that wiped smallpox off the planet. He’s using it as a guidebook for executing what is about to become one of the largest philanthropic efforts of all time.

Zaremba is one of OpenAI’s least well-known co-founders. He has spent more than a decade at the company across a range of efforts, from leading its early robotics efforts to starting the team that guides OpenAI’s personality and what became reasoning models. In March, he left the frontier research world to run AI “resilience” at OpenAI’s nonprofit foundation.

Zaremba and I spoke ahead of a post that the OpenAI Foundation published Monday morning titled “Resilience in the Age of AI,” which names four areas it will initially fund: biosecurity, cybersecurity, model safety, and AI’s effect on kids. After $100 million for fighting Alzheimer’s with AI in April and $250 million for researching “economic futures” last week, the initial $25 billion grant machine Zaremba helps oversee is spinning up.

/* */